Clinic study of domestic tirofiban during primary percutaneous coronary intervention

Objective To assess thrombolysis in myocardial infarction(TIMI) flow,the safety and efficacy of the national produced tirofiban in patients with ST-segment elevation myocardial infarction(STEMI) during primary percutaneous coronary intervention(PCI).Methods Sixty-eight patients with STEMI during primary PCI from March 2004 to June 2006 were divided into two groups,experimental group(tirofiban+PCI) 37 cases,control group(primary PCI) 31 cases.TIMI flow before and after operation including death,new onset myocardial infarction,persistent myocardial ischemic state,post-operation left ventricular ejection fraction(LVEF) and adverse drug effect(bleeding,platelet reduction) were observed in all cases.Results By using tirofiban before operation improved TIMI flow,TIMI flow of infarction related artery(IRA) in experimental group was higher as compared with control group(P(0.01)),There was no difference between two groups in TIMI grade flow after operation(P(0.05)).Reperfusion arrhythmia was less in experimental group((5.4%) vs(22.6%),P(0.05)).MACE rates in hospital experimental group was lower than that in control group((5.4%) vs(12.9%),P(0.05)),post-operation LVEF experimental group was more than that in control group((58.2)±(6.0) vs(50.4)±(10.63))(P(0.05)).There were no severe hemorrhage complications(severe hemorrhage or cerebral hemorrhrage) in both groups.The bleeding events tended to be higher in experimental group((10.8%) vs(3.2%),P(0.05)).Conclusion Tirofiban may improve TIMI flow of the IRA in patients with STEMI during emergency PCI,tirofiban +PCI is possible to become safe and effective reperfusion method.